TY - JOUR
T1 - Consensus recommendations for standard investigative workup
T2 - Report of the International Myeloma Workshop Consensus Panel 3
AU - Dimopoulos, Meletios
AU - Kyle, Robert
AU - Fermand, Jean Paul
AU - Rajkumar, S. Vincent
AU - San Miguel, Jesus
AU - Chanan-Khan, Asher
AU - Ludwig, Heinz
AU - Joshua, Douglas
AU - Mehta, Jayesh
AU - Gertz, Morie
AU - Avet-Loiseau, Hervé
AU - Beksaç, Meral
AU - Anderson, Kenneth C.
AU - Moreau, Philippe
AU - Singhal, Seema
AU - Goldschmidt, Hartmut
AU - Boccadoro, Mario
AU - Kumar, Shaji
AU - Giralt, Sergio
AU - Munshi, Nikhil C.
AU - Jagannath, Sundar
PY - 2011/5/5
Y1 - 2011/5/5
N2 - A panel of members of the 2009 International Myeloma Workshop developed guidelines for standard investigative workup of patients with suspected multiple myeloma. Both serum and urine should be assessed for monoclonal protein. Measurement of monoclonal protein both by densitometer tracing and/by nephelometric quantitation is recommended, and immunofixation is required for confirmation. The serum-free light chain assay is recommended in all newly diagnosed patients with plasma cell dyscrasias. Bone marrow aspiration and/or biopsy along with demonstration of clonality of plasma cells are necessary. Serum β2-microglobulin, albumin, and lactate dehydrogenase are necessary for prognostic purposes. Standard metaphase cytogenetics and fluorescent in situ hybridization for 17p, t(4;14), and t(14;16) are recommended. The skeletal survey remains the standard method for imaging screening, but magnetic resonance imaging frequently provides valuable diagnostic and prognostic information. Most of these tests are repeated during follow-up or at relapse.
AB - A panel of members of the 2009 International Myeloma Workshop developed guidelines for standard investigative workup of patients with suspected multiple myeloma. Both serum and urine should be assessed for monoclonal protein. Measurement of monoclonal protein both by densitometer tracing and/by nephelometric quantitation is recommended, and immunofixation is required for confirmation. The serum-free light chain assay is recommended in all newly diagnosed patients with plasma cell dyscrasias. Bone marrow aspiration and/or biopsy along with demonstration of clonality of plasma cells are necessary. Serum β2-microglobulin, albumin, and lactate dehydrogenase are necessary for prognostic purposes. Standard metaphase cytogenetics and fluorescent in situ hybridization for 17p, t(4;14), and t(14;16) are recommended. The skeletal survey remains the standard method for imaging screening, but magnetic resonance imaging frequently provides valuable diagnostic and prognostic information. Most of these tests are repeated during follow-up or at relapse.
UR - http://www.scopus.com/inward/record.url?scp=79956001465&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79956001465&partnerID=8YFLogxK
U2 - 10.1182/blood-2010-10-299529
DO - 10.1182/blood-2010-10-299529
M3 - Article
C2 - 21292778
AN - SCOPUS:79956001465
SN - 0006-4971
VL - 117
SP - 4701
EP - 4705
JO - Blood
JF - Blood
IS - 18
ER -